From Morphological Imaging To Molecular Targeting

The current progress in molecular medicine allows the identification of a plethora of new and often human-specific drug targets. An early in vivo validation of specific ligands binding to these targets in humans is needed to assess their potential for targeted imaging and radiotherapy. Radiopharmaceuticals are uniquely suitable for such target validation studies. The purpose of the Ernst Schering Research Foundation Workshop 48 was to offer a forum for an open exchange on the state of the art in the early development of such radiopharmaceuticals. Experts from academia, industry and regulatory authorities provided contributions covering the identification of targets, the necessary preclinical studies on the safety of ligands as well as their validation in human clinical trials.

The continuous progress in the understanding of molecular processes of disease formation and progression attributes an increasing importance to biomedical molecular imaging methods. The purpose of this workshop was to discuss and overview multiple applications and emerging technologies in the area of diagnostic imaging including its fundamental capabilities in preclinical research, the opportunities for medical care, and the options involving therapeutic concepts. The book provides the reader with state-of-the-art information on the different aspects of diagnostic imaging, illuminating new developments in molecular biology, imaging agents and molecular probe design, and therapeutic techniques.

Today combined oral contraceptives are the most convenient and accepted way of hormonal contraception. Nevertheless, there is a constant demand in the medical community and consumer market for innovation, additional benefits during use and lower hormonal load despite the high safety profile of available products. At the Ernst Schering Research Foundation Workshop 52 new perspectives and mechanisms for tissue-selective, estrogen-free contraception were discussed. The aim of the workshop was to bring together experts in the field of molecular and pharmacodynamic action of progestins with clinicians and medical experts to discuss potential medical endpoints, physiological reactions and (bio)marker useful to describe the tissue selectivity and the contraceptive action of new progestins in different target organs. A major success factor for the realization of these new concepts is a deeper understanding of local pharmacological responses to progestins in general and to new progestins in particular. TOC:New Strategies for CNS Repair; Heterogeneity of Multiple Sclerosis: Implications for Therapy Targeting Regeneration; The Neuroprotective Effect of Inflammation: Implications for the Therapy of Multiple Sclerosis; Fibroblast Growth Factors in Oligodendrocyte Physiology and Myelin Repair; White Matter Progenitor Cells Reside in an Oligodendrogenic Niche; At the Interface of the Immune System and the Nervous System: How Neuroinflammation Modulates the Fate of Neural Progenitors in vivo; Remyelination and Restoration of Axonal Function by Glial Cell Transplantation; Gene and Stemm Cell Therapy for Autoimmune Demyelination; Novel Gene Therapeutic Strategies for Neurodegenerative Diseases; Measuring Injury and Repair of Myelin and Neurons in Multiple Sclerosis; The Role of Polypeptide Growth Factors in Recovery from Stroke

Drug Safety Evluation Comprehensive and practical guide presenting a roadmap for safety assessment as an integral part of the development of drugs and therapeutics This fourth edition of Drug Safety Evaluation maintains the central objective of presenting an all-inclusive practical guide for those who are responsible for ensuring the safety of drugs and biologics to patients, healthcare providers, those involved in the manufacture of medicinal products, and all those who need to understand how the safety of these products is evaluated and shepherding valuable candidates to market. Individual chapters address specific approaches to evaluation hazards, including problems that are encountered and their solutions. Also covered are the scientific and philosophical bases for evaluation of specific concerns (e.g., carcinogenicity, development toxicity, etc.) to provide both understanding and guidance for approaching the new problems that have come to face both our society and the new challenges they brought. The many changes in regulatory requirements, pharmaceutical development, technology, and the effects of Covid on our society and science have required both extensive revision to every chapter and the addition of four new chapters. Specific sample topics covered in Drug Safety Evaluation include: The drug development process and the global pharmaceutical marketplace and regulation of human pharmaceutical safety Sources of information for consideration in study and program design and in safety evaluation Electronic records, reporting and submission, screens in safety and hazard assessment, and formulations, routes, and dosage regimens Mechanisms and endpoints of drug toxicity, pilot toxicity testing in drug safety evaluation, and repeat dose toxicity Genotoxicity, QSAR tools for drug safety, toxicogenomics, nonrodent animal studies, and developmental and reproductive toxicity testing An appendix which provides an up to date guide to CROs for conducting studies Drug Safety Evaluation was written specifically for the pharmaceutical and biotechnology industries, including scientists, consultants, and academics, to show a utilitarian yet scientifically valid path to the everyday challenges of safety evaluation and the problem solving that is required in drug discovery and development.

Understanding the biology of brain function is a great challenge and a major goal of modern science. The brain is one of the last great frontiers in science, and the unraveling of its mysteries is comparable in complexity to efforts in space exploration. A fundamental goal of neuroscience is to understand how neurons generate behavior and the pathophysiology of different mental and neurological diseases. The aim of this book is to describe recent discoveries about the basic operations of the brain and to provide an introduction to the adaptations for specific types of information processing.

This book comprehensively reviews the recent advances in nanomaterial-based molecular imaging, diagnostics, and personalized therapy. It discusses the novel biocompatible fluorescent nanomaterials, their synthesis, and modern state of art characterization, as well as the various strategies for immobilization of biomacromolecules on the nanomaterial surface and approaches for increasing their stability. In addition, the book describes the synthesis of lectin nanoconjugates using different types of biocompatible raw materials and their systematic characterization. Lastly, it presents our current understanding of the biomolecular carona, which affects nanoparticle-based targeted drug delivery, and examines the conceptual approaches to improve the in-vivo efficacy of targeted drug delivery.

This open access book describes marked advances in imaging technology that have enabled the visualization of phenomena in ways formerly believed to be completelyimpossible. These technologies have made major contributions to the elucidation of the pathology of diseases as well as to their diagnosis and therapy. The volume presents various studies from molecular imaging to clinical imaging. It also focuses on innovative, creative, advanced research that gives full play to imaging technology inthe broad sense, while exploring cross-disciplinary areas in which individual research fields interact and pursuing the development of new techniques where they fuse together. The book is separated into three parts, the first of which addresses the topic of visualizing and controlling molecules for life. Th e second part is devoted to imaging of disease mechanisms, while the final part comprises studies on the application of imaging technologies to diagnosis and therapy. Th e book contains the proceedings of the 12th Uehara International Symposium 2017, “Make Life Visible” sponsored by the Uehara Memorial Foundation and held from June 12 to 14, 2017. It is written by leading scientists in the field and is an open access publication under a CC BY 4.0 license.

Today, treatment options for cancer patients typically include surgery, radiation therapy, immunotherapy, and chemotherapy. While these therapies have saved lives and reduced pain and suffering, cancer still takes millions of lives every year around the world. Researchers are now developing advanced therapeutic strategies such as immunotherapy, targeted therapy, and combination nanotechnology for drug delivery. In addition, the identification of new biomarkers will potentiate early-stage diagnosis. Molecular Targets and Cancer presents information about cancer diagnosis and therapy in a simple way. It covers several aspects of the topic with updated information on par with medical board levels. The book features contributions from experts and includes an overview of cancer from basic biology and pathology, classifications, surveillance, prevention, diagnosis, types of cancer, treatment and prognosis. The second part of this book discusses specialized topics in clinical oncology which include the pathophysiology of various types of cancer, cancer screening, different types of cancer surgery, cancer stem cell-targeted immunotherapy, nanotechnology for precision medicine applications in cancer and cancer surveillance. This comprehensive guide is a valuable resource for oncologists, researchers, and all medical professionals who work in cancer care and research.